Nasdaq atai.

Nov 24, 2023 · The latest ATAI Life Sciences stock prices, stock quotes, news, and ATAI history to help you invest and trade smarter. ... (NASDAQ: ATAI) reported its financial results and corporate updates for ...

Nasdaq atai. Things To Know About Nasdaq atai.

Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.We are currently testing DMX-1002, atai’s oral formulation of ibogaine, in an ongoing Phase 1/2 trial to evaluate its safety, tolerability, pharmacokinetics, and efficacy. We expect initial data ...Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis.atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet ...NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...

Mar 7, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ... About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. NVIDIA Corporation Common Stock. ATAI Life Sciences N ... Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 million to advance multiple clinical and discovery programs.

“In just four years with Florian as CEO we raised more than $600 million, grew the staff to more than 100, brought eight compounds into clinical-stage trials, and took Atai public on the Nasdaq ...

-5.91%. Nasdaq Biotechnology Ishares ETF. VHT, 0%, -1.78%. Healthcare ETF ... atai Life Sciences B.V. is based in BERLIN. See More. ATAI Related stocks. Symbol ...Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.RedHill Biopharma Ltd. (NASDAQ:RDHL) said Medi-Cal - California's Medicaid Health Care program covering two million patients - has added its Talicia to its contract drug list for H. pylori ...Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis. Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...

Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis.

First, MindMed (Nasdaq: MNMD, NEO: MMED) will present data from their Phase 2a clinical trial attempting to treat Generalized Anxiety Disorder using a large dose of LSD paired with therapy.. For serious MindMed investors, this will be a big moment. While in the short to medium-term stocks can fluctuate wildly, especially speculative biotech …

atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the launch of TryptageniX.To compile our list of the best German stocks to buy, we first made a list of all German firms that are trading on the NASDAQ and NYSE exchanges. Then, those firms with the greatest number of hedge fund investors during Q2 2023, and the top German stocks are as follows. 12 Best German Stocks To Buy Now 12. Atai Life Sciences N.V. (NASDAQ:ATAI)111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... ATAI ATAI Life Sciences. Close 12/01 16:00 ET. 1.120. +0.080 +7.69%. High 1.150 ... (NASDAQ:ATAI) shares closed up 4.67% at $1.12Mind Medi. Benzinga11-23 04:30 ET.In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. ... NASDAQ: ATAI Atai Life Sciences. Market Cap. $173M. Today's Change (-7.14% ...For ATAI Life Sciences NV (NASDAQ:ATAI), Canaccord Genuity initiated coverage, by setting the current rating at Buy. The stock has a 52-week-high of $22.91 and a 52-week-low of $16.50.Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

Aug 15, 2022 ... atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Oct 2, 2023 · NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... Nov 17, 2023 ... atai Life Sciences N.V. (ATAI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy).Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in the first quarter of 2023.atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023.Aug 15, 2022 ... atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...

Apr 20, 2023 · With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...

Instrument Name Atai Life Sciences N.V. Instrument Symbol (ATAI-Q). Instrument Exchange NASDAQ ; Previous Close 1.1200 ; 52-Week High/Low 3.6500 1.0400 ; Volume ...Analyst's Opinion · Consensus Rating. Atai Life Sciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...RedHill Biopharma Ltd. (NASDAQ:RDHL) said Medi-Cal - California's Medicaid Health Care program covering two million patients - has added its Talicia to its contract drug list for H. pylori ...DarioGaona/iStock via Getty Images. Atai Life Sciences (NASDAQ:ATAI) has been making great progress in advancing several drugs from its pipeline on multiple fronts.In particular, it is advancing a ...NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Atai. On April 7, 2021, Atai Life Sciences , (NASDAQ: ATAI) a clinical-stage biopharmaceutical company developing psychedelics and non-psychedelic compounds for mental health wellness, acquired a majority stake in Delaware-based Psyber, a company working on a brain-to-computer (BCI) interface device. It is hoped that the Psyber brain-to ...For example, they have invested more money into Cybin (NYSE: CYBN) than they have into larger companies such as GH Research (Nasdaq: GHRS) and atai Life Sciences (Nasdaq: ATAI). Obviously, they expect Cybin to have larger returns.

Cramer said he likes Enterprise Products Partners L.P. (NYSE:EPD) as it has good dividend, growing volumes and solid management. The "Mad Money" host said Doximity, Inc. (NASDAQ:DOCS) is good, but ...

ATAI's stock price has decreased by -68.7% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 4 stock analysts, the average 12-month stock price forecast for ATAI stock stock is $13.5, which predicts an increase of 1,116.22%.

atai Life Sciences (NASDAQ:ATAI) is trading at $1.42, falling from Friday 1’s trading around $1.53 and Friday 25’s close at $1.54. Incannex Healthcare (NASDAQ:IXHL) is trading around $1.34, ...Atai Life Sciences (NASDAQ: ATAI) is another clinical-stage biopharmaceutical company that seeks to transform the treatment of mental health conditions using innovative psychedelic-based drugs ...EVgo, Inc. (NASDAQ:EVGO) fell 14.3% to close at $16.19 following negative analyst coverage from Credit Suisse. Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 13.8% to close at $12.85 following Q3 ...COMPASS Pathways (NASDAQ:CMPS), GH Research (NASDAQ:GHRS), atai Life Sciences (NASDAQ:ATAI), IntelGenx Technologies (OTCQB:IGXT) and Filament Health (OTCQB:FLHLF) reported their first quarter ...Atai Life Sciences (NASDAQ:ATAI) is one of the leading biotech companies discovering and developing treatments derived from psychedelic compounds. Atai already has an MDMA-derived drug in its ...The average one-year price target for ATAI Life Sciences N.V. (NASDAQ:ATAI) has been revised to 12.57 / share. This is an increase of 5.04% from the prior estimate of 11.97 dated August 31, 2023.Apr 13, 2023 · NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... On February 16, Atai Impact, the philanthropic program of Atai Life Sciences (NASDAQ:ATAI) announced it has donated $500,000 to the Multidisciplinary Association for Psychedelic Studies (MAPS ...Oct 31, 2023 · Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7 Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders. atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently ...

Gainers Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) gained 34.1% to settle at $12.58 on Wednesday. ... Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 31.9% to close at $6.82 on Wednesday.NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders ...ATAI Life Sciences N.V. Common Shares (ATAI) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, the company announced that the Food and Drug Administration (FDA) gave the company Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R …Instagram:https://instagram. stock mitkfinancial advisors louisville kywealth management teambroker cfd usa NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the …Atai Life Sciences (NASDAQ:ATAI) closed at $1.29, almost the same as Friday 22’s closing price $1.30 and also down from past weeks’ closings ($1.45 and $1.43.) td ameritrade margin rates per day5 stocks under 5 NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix.. PsyProtix is a precision psychiatry company focused ... stock simulator app NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ...Apr 13, 2023 · NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...